Puja P. Khanna

Puja P. Khanna

Auto-generated profile, based on publicly available information

Puja P. Khanna

P.P. Khanna, MD, MPH, Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2014 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Closed access
PKPuja P. Khanna
Puja P. Khanna
HGHeather S. Gladue
Heather S. Gladue
MSManjit K. Singh
Manjit K. Singh
John FitzGeraldJohn FitzGerald
John FitzGerald
SBSangmee Bae
Sangmee Bae
DKDinesh Khanna
Dinesh Khanna

19 May 2021 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
PDF file
PKPuja P. Khanna
Puja P. Khanna
DKDinesh Khanna
Dinesh Khanna
GCGary Cutter
Gary Cutter
JFJeff Foster
Jeff Foster
JMJoshua Melnick
Joshua Melnick
KSKenneth G. Saag
Kenneth G. Saag

17 November 2015 in Postgraduate Medicine
Verified
Journal Article
Closed access
PKPuja Khanna
Puja Khanna
DKDinesh Khanna
Dinesh Khanna
CSChris Storgard
Chris Storgard
SBScott Baumgartner
Scott Baumgartner
RMRobert Morlock
Robert Morlock
Background: Gout continues to be underdiagnosed and poorly managed despite the potential for cure. US and European management guidelines recommend treating to target serum urate (sUA) levels of <6 mg/dL (or <5 mg/dL to durably improve severe symptoms), with use of regular sUA monitoring, but studies suggest relatively poor adherence to these recommendations. This study investigates the real-world state of gout management in the United States by describing the characteristics of a large patient population treated in primary care and rheumatology settings. Methods: A retrospective chart audit, conducted among 124 primary care physicians and 125 rheumatologists, included 1245 patients with gout. Physicians completed structured case report forms capturing 12 months of sUA laboratory values, flare counts, comorbidities, types and doses of treatment, treatment duration, diagnosis date, physician specialty and socio-demographic factors. Focusing on the xanthine oxidase inhibitors (n = 858), descriptive statistics and multivariate models characterized relationships between patient characteristics, disease control, and treatment. Results: Only 83 (11%) patients achieved disease control, defined as a 12-month average sUA ≤6 mg/dL, no flares, and no tophi. Patients with greatest disease severity (defined as sUA >6 mg/dL, ≥2 flares per year, and tophi) were more likely to have kidney disease and other comorbidities. In a multivariate model, predictors of more severe gout were rheumatologist (vs primary care) management, febuxostat (vs allopurinol) use and presence of comorbid conditions. Conclusion: Our findings confirm the inadequacy of gout management in the real-world setting. Regular monitoring, including sUA measurement as recommended in guidelines, is important to assess gout control. Our analyses also demonstrate that patients with more severe gout are more likely to have comorbid conditions, be treated by a specialist and use newer therapies.

1 April 2014 in Arthritis Care & Research
Verified
Journal Article
Open access
PDF file
VNVivek Nagaraja
Vivek Nagaraja
RHRon D. Hays
Ron D. Hays
PKPuja P. Khanna
Puja P. Khanna
BSBrennan M. R. Spiegel
Brennan M. R. Spiegel
LCLin Chang
Lin Chang
DKDinesh Khanna
Dinesh Khanna
Objective: Gastrointestinal (GI) involvement is common in patients with systemic sclerosis (SSc; scleroderma). The Patient‐Reported Outcomes Measurement Information System (PROMIS) GI symptom item bank captures upper and lower GI symptoms (reflux, disrupted swallowing, nausea/vomiting, belly pain, gas/bloating/flatulence, diarrhea, constipation, and fecal incontinence). The objective of this study was to evaluate the construct validity of the PROMIS GI bank in SSc.Methods: A total of 167 patients with SSc were administered the PROMIS GI bank and the University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Scale (GIT 2.0) instrument. GIT 2.0 is a multi‐item instrument that measures SSc‐associated GI symptoms. Product‐moment correlations and a multitrait–multimethod analysis of the PROMIS GI scales with the GIT 2.0 symptom scales were used to evaluate convergent and discriminant validity.Results: Patients with SSc GI involvement had PROMIS GI scale scores 0.2–0.7 SD worse than the US general population. Correlations among scales measuring the same domains for the PROMIS GI and GIT 2.0 measures were large, ranging from 0.61 to 0.87 (average r = 0.77). The average correlation between different symptom scales was 0.22, supporting discriminant validity.Conclusion: This study provides support for the construct validity of the PROMIS GI scales in SSc. Future research is needed to assess the responsiveness to change of these scales in patients with SSc.

15 January 2022 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
PKPuja Khanna
Puja Khanna
Any human who has ever experienced an acute gout flare understands how painful and debilitating this condition is. Unfortunately, due to the episodic nature of these acute flares that occur randomly due to transient fluctuations in urate levels, patients often underreport these attacks.

1 April 2018 in The Lancet Diabetes & Endocrinology
Verified
Journal Article
Closed access
PKPuja P Khanna
Puja P Khanna